retatrutide and cholesterol ​"Triple-Hormone" Drug Shows Record Weight Loss: At the American Diabetes Association's 2026 Scientific Sessions, researchers unveiled phase 3 trial results for retatrutide, the first therapy to Retatrutide Weight Loss Results:Trial Data

Le Retatrutide 10mg (research code LY3437943, also known as GLP-3) is a next-generation triagonist peptide developed by Eli Lilly

Research peptides are manufactured to lower standards with no regulatory oversight

That's not a finding suggesting GLP-1s should be avoided - it's a finding suggesting that musculoskeletal support, including resistance training, isn't optional for women on these medications

Retatrutide storage requirements Retatrutide is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

At the same time, glycemic control remains critical

Vitamin B12 injections may support energy and normal metabolic function